{
  "ticker": "LLY",
  "target_date": "2025-08-05",
  "actual_date": "2025-08-05",
  "collected_at": "2025-12-08T12:06:09.930546",
  "price": {
    "open": 762.77,
    "high": 767.13,
    "low": 756.74,
    "close": 763.1505737304688,
    "volume": 3615200,
    "change_1d_pct": -0.4,
    "change_7d_pct": -5.75,
    "change_30d_pct": -0.61
  },
  "technicals": {
    "rsi_14": 44.13,
    "sma_20": 776.59,
    "sma_50": 772.2,
    "macd": -3.749,
    "macd_signal": -0.681,
    "macd_histogram": -3.069,
    "bb_upper": 815.86,
    "bb_lower": 737.32,
    "price_vs_sma20_pct": -1.73,
    "price_vs_sma50_pct": -1.17,
    "volume_ratio": 1.01
  },
  "fundamentals": {
    "market_cap": 891795210240,
    "pe_ratio": 48.740814,
    "forward_pe": 43.901146,
    "price_to_book": 37.45482,
    "price_to_sales": 15.008385,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.54,
    "pct_from_52w_low": 59.48
  },
  "macro": {
    "spy": {
      "price": 626.23,
      "change_1d_pct": -0.51,
      "change_7d_pct": -1.41
    },
    "vix": {
      "level": 17.85,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.2
    },
    "dollar_index": {
      "level": 98.78
    },
    "gold": {
      "price": 3381.9
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management",
      "source": "Yahoo",
      "datetime": 1754436600,
      "summary": "Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscapeDesigned to address emerging areas of patient need, including long-term weight management, co-morbid metab",
      "url": "https://finnhub.io/api/news?id=644e01a9e1569ace1cc5c9a1d1ae600f2dbaf272b4018a31b02885207b7b5a5d"
    },
    {
      "headline": "Novo Nordisk Growth Profile Seen Deteriorating Amid US Compounding Challenges, UBS Says in Downgrade",
      "source": "Yahoo",
      "datetime": 1754424820,
      "summary": "Novo Nordisk's (NVO) \"rapidly\" deteriorating growth profile amid continued mass compounding of obesi",
      "url": "https://finnhub.io/api/news?id=102147a34bdaf6bcbf585014352ed00ad19159a82cf4a808b0a7406d8febad43"
    },
    {
      "headline": "Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update",
      "source": "Yahoo",
      "datetime": 1754424060,
      "summary": "Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE\u00ae (fostamatinib disodium hexahydrate), GAVRETO\u00ae (pralsetinib) and",
      "url": "https://finnhub.io/api/news?id=a963e2b4f8328dfaa984c43a4a2ebf204c90d9b59e242d5b1fbcfb23bb1082d5"
    },
    {
      "headline": "Eli Lilly stock drops after Trump unleashes 250% pharma tariff warning",
      "source": "Yahoo",
      "datetime": 1754421372,
      "summary": "Trump tariff shock hits Eli Lilly as $27B U.S. plan fails to impress",
      "url": "https://finnhub.io/api/news?id=83241685863c1e20a711364e4c9f500cc4119547ac516f33ab08ca016bf2a714"
    },
    {
      "headline": "Why Novo Nordisk Stock Is Down Again Today",
      "source": "Yahoo",
      "datetime": 1754414546,
      "summary": "Are you brave enough to catch this falling knife?",
      "url": "https://finnhub.io/api/news?id=14e3a5dcccc40d757b6232c886e970f48d5ed9c047ad99b177a13005e59edc3b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-08-04",
      "description": "xslF345X05/wk-form4_1754338601.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000198/xslF345X05/wk-form4_1754338601.xml"
    },
    {
      "form": "4",
      "date": "2025-07-25",
      "description": "xslF345X05/form4-07252025_040701.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925020284/xslF345X05/form4-07252025_040701.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753219662.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000196/xslF345X05/wk-form4_1753219662.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753217727.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000194/xslF345X05/wk-form4_1753217727.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753216439.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000188/xslF345X05/wk-form4_1753216439.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}